~~<i id='C0FB44FDB0'><strike id='C0FB44FDB0'><tt id='C0FB44FDB0'><pre id='C0FB44FDB0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

leisure time

author：explore 2025-10-01 23:02:23 - browse：79

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

explore

knowledge

entertainment

Wikipedia

explore

hotspot

SanofiTheFoodandDrugAdministrationapprovedamonoclonalantibodytoprotectinfantsandyoungchildrenfromsev

WSS

Ambulance rides for just $100? Advisers want major billing fixes

Custom gene therapy hints at new path for rare disease treatments

Key House panel plots a new health care package

Sanofi seeks simpler, safer CRISPR sickle cell cure

How dance can help nurses traumatized by Covid

Custom gene therapy hints at new path for rare disease treatments

Wikipedia

leisure time

explore

Affirmative action in medical school literally saved lives

A clever new way to fix Medicaid and graduate medical education

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Dobbs anniversary: the lost opportunity of abortion as health care

Group opposing PBM reform sets lobbying record

What does generative AI mean for health care? We asked experts

Sanofi CEO defends move to abandon profit guidance, boost research

Medicare details structure of new drug price negotiation program

Key House panel plots a new health care package

knowledge

How Medicaid coverage policies for immigrants impact new moms

FDA approves potent Eli Lilly obesity drug, Zepbound

MoonLake credibility takes another hit with mid

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Biotech incubator Curie.Bio graduates its first startup

Key House panel plots a new health care package

entertainment

Wikipedia

explore

hotspot